[Clinical experiences with the radiation sensitizer MTDQ (Sensorad) in advanced malignancies of the head and neck region and in uterine cancer].
33 patients with malignancies of the head and neck and 9 patients with carcinoma uteri received Sensorad combined with megavolt-therapy in a placebo controlled trial. 35% of the Sensorad treated patients with head and neck cancer showed an early radiomucositis. A full regression was achieved in 15 patients and a partial regression in 18 patients thus the drug helped in 79% of the patients treated. No regression was noted in 6 patients and a progression in 3, that means in 21% of patients no benefit was detected. In the placebo control group a benefit was proved for 35% of the patients whereas 65% of the patients showed no benefit. The proportion of benefit to no benefit was 3.66 in the Sensorad group compared to 0.54 in the placebo group. The patients with carcinoma uteri all showed a benefit from the treatment with Sensorad. The number of adverse reactions was small. 4 patients had nausea and gastrointestinal symptoms, 2 allergic reactions and 3 elevated SGOT (21.4%).
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011804:Quinolines / Q000627:therapeutic use*; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000209:etiology; D014594:Uterine Neoplasms / Q000532:radiotherapy*
D010919:Placebos; D011804:Quinolines; C011923:6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)
Klinische Erfahrungen mit dem Radiosensitizer MTDQ (Sensorad) bei fortgeschrittenen Malignomen des Kopf-Hals-Bereiches und bei Gebärmutterkrebs.